The degree of complexity and crossover within MAPK signaling, and also shifts in pathways such as nuclear factor κB signaling, could also explain the modest effect of p38 inhibitors. The p38α ...

(A) PFS and (B) OS in class 2 versus other MAP2K1 mutant tumors in the whole MAPK targeted therapy-treated cohort. (C) PFS and (D) OS in class 2 versus other MAP2K1 mutant tumors in patients treated ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further ...

inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK pathway, according to a study published in JACC ...

and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS/MAPK pathway inhibition. In contrast to currently available MEK-only inhibitors, avutometinib ...

inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK pathway, according to a study published today in ...

“With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven ...